bluebird bio price target raised to $58 from $51 at Piper Jaffray Piper Jaffray raised its price target for bluebird bio (BLUE) shares to $58 saying the beta thal market provides opportunity for both bluebird and Biogen (BIIB). Piper sees a possible market split should both companies' data remain positive. It keeps an Overweight rating on bluebird bio.
News For BLUE From The Last 14 Days
Check below for free stories on BLUE the last two weeks.